The most common on-target, off-tumor toxicity caused by CAR-T cells targeting CD19, CD22, and BCMA is profound B cell aplasia, but this could be treated with intravenous immunoglobulin (IVIG) replacement therapy. Here, CD19 is linked to neoplasm.